Skip to content
Search

Latest Stories

PHE introduces new surveillance system for early coronavirus detection

Public Health England (PHE) today announced a new surveillance system for early detection of the novel coronavirus, COVID-19.

Part of the efforts to strengthen the existing systems and to prepare for and prevent wider transmission of the virus, the new system will be implemented in intensive care units and Severe Respiratory Failure (ECMO) Centres of some NHS hospitals.


It will enable the agency to identify early evidence of spread within England.

Samples will be tested from patients with severe respiratory infections who do not meet the current case definition of COVID-19. Depending on the results, patients will be given the support they need and rapid public health actions will be taken.

Eight hospitals have so far confirmed their participation in the scheme.

“There is no change in risk for the public but taking this preparatory step now will enable us to better detect and contain the spread of the virus. The UK’s infection control procedures are world-leading, and the system we are announcing today further strengthens our response,” said Professor Yvonne Doyle, PHE’s Medical Director.

A programme of testing with a network of around 100 primary care sites across England will also complement the detection system in hospitals so that both mild and more unwell cases can be found.

PHE clarified that the new process will not apply to patients meeting the current coronavirus case definition, who will continue to be isolated and tested as appropriate, and the test results will not be affected.

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less